Commentary on “Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer”

2012 ◽  
Vol 106 (4) ◽  
pp. 527-528
Author(s):  
Yusuf Yildirim ◽  
Ibrahim E. Ertas
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer ◽  
Response Criteria

scholarly journals Erratum: Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer

2012 ◽  
Vol 107 (6) ◽  
pp. 680-680
Author(s):  
Bellati Filippo ◽  
Gasparri Maria Luisa ◽  
Caccetta Jlenia ◽  
Palaia Innocenza ◽  
Benedetti Panici Pierluigi
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer ◽  
Response Criteria

Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer

2012 ◽  
Vol 106 (4) ◽  
pp. 529-529 ◽  
Author(s):  
Bellati Filippo ◽  
Gasparri Maria Luisa ◽  
Caccetta Jlenia ◽  
Palaia Innocenza ◽  
Benedetti Panici Pierluigi
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer ◽  
Response Criteria

Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients

2021 ◽  
Author(s):  
Mukur Dipi Ray ◽  
Suryanarayana S.V. Deo ◽  
Lalit Kumar ◽  
Manish Kumar Gaur
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
Advanced Stages ◽  
Selection For ◽  
Selection Of Patients ◽  
Selection Of

In cases of ovarian carcinoma, primary cytoreductive surgery (CRS) is the standard treatment up to stage IIIB, but patient selection for neoadjuvant chemotherapy (NACT) in selected cases is controversial. A total of 200 patients with advanced ovarian cancer were analyzed retrospectively, according to specific selection criteria. Primary CRS was performed in 95 patients (47.5%) and interval CRS after 3–6 cycles of NACT was performed in 105 patients (52.5%). After median follow-up of 35 months, 5-year overall survival was 53.7% in the upfront CRS group and 42.2% in the NACT group. Primary CRS is the standard in advanced stages of ovarian carcinoma, but in certain subset of patients, NACT is preferred. Identifying that group is challenging but feasible. Proper selection of patients is key to successful outcomes.

scholarly journals An increased ratio of cytotoxic to suppressive T cells after neoadjuvant chemotherapy (NACT) is prognostic in advanced ovarian cancer

2017 ◽  
Vol 28 ◽  
pp. v334
Author(s):  
A. Khairallah ◽  
A. Auguste ◽  
A. Leary ◽  
C. Genestie ◽  
P. Pautier ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Cells ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document